BioCentury
ARTICLE | Strategy

The product promised land

August 28, 2006 7:00 AM UTC

By picking up E40 million ($51.3 million) in a series C round last week, Ablynx N.V. will finance its transition from simply trying to retain some marketing rights on partnered programs to becoming a fully fledged product company. Its initial focus will be to develop its nanobodies against clinically validated targets.

A nanobody is a functional antigen-binding domain derived from an antibody heavy chain...